共 58 条
[1]
Ducreux M(2015)Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v56-v68
[2]
Caramella C(2017)NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma, Version 2.2017 J Natl Compr Cancer Netw 15 1028-1061
[3]
Hollebecque A(2017)Second-line chemotherapy for advanced pancreatic cancer: which is the best option? Crit Rev Oncol Hematol 115 1-12
[4]
Tempero MA(2016)Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 34 2784-2796
[5]
Malafa MP(2013)Recent progress in pancreatic cancer CA Cancer J Clin 63 318-348
[6]
Al-Hawary M(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825
[7]
Aprile G(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703
[8]
Negri FV(2016)Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer Expert Rev Anticancer Ther 16 485-492
[9]
Giuliani F(2016)Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Lancet 387 545-557
[10]
Sohal DP(2014)PD-0018 An indirect treatment comparison and cost effectiveness analysis comparing FOLFIRINOX with nab-paclitaxel plus gemcitabine for first-line treatment for patients with metastatic pancreatic cancer Ann Oncol 25 ii11-ii12